The Covishield Covid-19 vaccine, which is being manufactured in India by Serum Institute of India, is effective against the B.1.617.1 strain of the Coronavirus, a study has found.
The B.1.617.1 variant of the Covid-19 virus is considered to be responsible for surge of the cases in India.
A study by the Indian Council of Medical Research (ICMR) has concluded that "Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in vaccinated individuals”.
"The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naive with a significant difference (p<0.0001) in NAb titer against B.1 and B.1.617.1," said the study published in pre-print server bioRxiv.
Till date, over 170 million doses of vaccine have been administered to Indian citizens with two approved vaccines- Covishield (Astrazeneca-Oxford) and Bharat Biotech's Covaxin.
Earlier, the ICMR in a study has said that the indigenous Covid-19 vaccine was effective against the various strains of the Covid-19 virus including B.1.617.1, B.1.1.7, B.18.104.22.168 and variants.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.